The closing price of Elanco Animal Health Inc (NYSE: ELAN) was $15.43 for the day, down -0.96% from the previous closing price of $15.58. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 3385439 shares were traded.
Ratios:
Our analysis of ELAN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 58.07. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 2.75. In the meantime, Its Debt-to-Equity ratio is 0.95 whereas as Long-Term Debt/Eq ratio is at 0.94.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on January 05, 2024, Upgraded its rating to Buy and sets its target price to $20 from $13 previously.
On December 19, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $17.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 15, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 08 ’24 when DOYLE WILLIAM F bought 15,000 shares for $16.30 per share. The transaction valued at 244,500 led to the insider holds 61,330 shares of the business.
Harrington Michael J bought 3,100 shares of ELAN for $50,494 on Mar 08 ’24. The Director now owns 77,594 shares after completing the transaction at $16.29 per share. On Mar 06 ’24, another insider, HOOVER R DAVID, who serves as the Director of the company, bought 20,000 shares for $16.14 each. As a result, the insider paid 322,808 and bolstered with 185,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 7.68B and an Enterprise Value of 13.10B. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.72 while its Price-to-Book (P/B) ratio in mrq is 1.22. Its current Enterprise Value per Revenue stands at 2.97 whereas that against EBITDA is -58.49.
Stock Price History:
The Beta on a monthly basis for ELAN is 1.31, which has changed by 69.19% over the last 52 weeks, in comparison to a change of 26.95% over the same period for the S&P500. Over the past 52 weeks, ELAN has reached a high of $16.88, while it has fallen to a 52-week low of $7.88. The 50-Day Moving Average of the stock is 15.81, while the 200-Day Moving Average is calculated to be 12.73.
Shares Statistics:
ELAN traded an average of 4.39M shares per day over the past three months and 2.73M shares per day over the past ten days. A total of 492.85M shares are outstanding, with a floating share count of 488.14M. Insiders hold about 0.98% of the company’s shares, while institutions hold 99.09% stake in the company. Shares short for ELAN as of Mar 15, 2024 were 12.98M with a Short Ratio of 2.96, compared to 11.97M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.63% and a Short% of Float of 3.20%.
Earnings Estimates
The firm’s stock currently is rated by 10 analysts. On average, analysts expect EPS of $0.26 for the current quarter, with a high estimate of $0.27 and a low estimate of $0.25, while EPS last year was $0.45. The consensus estimate for the next quarter is $0.24, with high estimates of $0.27 and low estimates of $0.2.
Analysts are recommending an EPS of between $0.97 and $0.88 for the fiscal current year, implying an average EPS of $0.92. EPS for the following year is $1.06, with 12 analysts recommending between $1.14 and $0.96.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $1.18B to a low estimate of $1.17B. As of the current estimate, Elanco Animal Health Inc’s year-ago sales were $1.26B, an estimated decrease of -6.50% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $1.15B, an increase of 9.10% over than the figure of -$6.50% in the same quarter last year. There is a high estimate of $1.18B for the next quarter, whereas the lowest estimate is $1.09B.
A total of 11 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.54B, while the lowest revenue estimate was $4.46B, resulting in an average revenue estimate of $4.5B. In the same quarter a year ago, actual revenue was $4.42B, up 1.80% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $4.67B in the next fiscal year. The high estimate is $4.76B and the low estimate is $4.52B. The average revenue growth estimate for next year is up 3.90% from the average revenue estimate for this year.
